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OBJECTIVES: Diabetes is a serious, costly metabolic disorder with a rising preva-
lence worldwide. Chromium has long been shown to improve insulin sensitivity,
lipid profiles, and blood glucose in insulin resistance and type-2 diabetic patients.
METHODS: All relevant databases were searched up to December 2011 limited to
human studies in English language. Clinical studies in newly onset patients with
type-2 diabetes reporting use of chromium at least for 4 weeks and outcomes of
fasting blood glucose (FBG), hemoglobin A1C (HbA1c), triglyceride (TG), low density
lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL) and body
mass index (BMI) were identified. Data of before and after use of chromium intake
were compared. RESULTS: The functional outcome data from clinical studies re-
vealed that our of 834 studies, 39 met inclusion criteria. Seventy present of articles
demonstrated a decrease in FBS while 23% showed an increase. Forty-seven per-
cent of studies showed an increase in HbA1c, while 15% a decrease. TG in 60% of
studies showed an increase while in 15% a reductionwas reported. LDL cholesterol
in 60% of studies showed a decrease and in the rest there was no report of increase.
Forty percent of studies showed a decrease in HDL cholesterol while 30% showed
an increase. BMI in 40% of studies decreased and in 7% of cases increased.
CONCLUSIONS: In clinical studies, average of mentioned parameters were im-
proved significantly after administration of chromium in patients with type 2 dia-
betes in a dose-dependent manner with no side effects. This systematic review
indicates beneficial effects of chromium in diabetic patients.
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OBJECTIVES: Growing rates of obesity and type 2 diabetes mellitus (T2DM) are
major health problems in China. Bariatric surgery is an effective treatment for
patientswith clinically severe obesity additionally improving co-morbidities, while
metabolic surgery is a procedure aimed at resolution of T2DM. The main objective
of our study was to assess the efficacy of both procedures performed on Chinese
population. METHODS: A comprehensive search was performed in PUBMED and
websites of Chinesemedical databases and journals including: www.wanfangdata.
com, www.cqvip.com, www.cnki.net, www.docin.com, wenku.baidu.com. Studies
met the inclusion criteria if they enrolled obese Chinese patients with or without
T2DM undergoing following laparoscopic procedures: sleeve gastrectomy, Roux-
en-Y gastric bypass, adjustable gastric banding, single-incision sleeve gastrectomy.
RESULTS:Our search retrieved 17 studies (2339 patients) of which 7 included T2DM
patients (N  374) exclusively. Overall, mean BMI reduction one year following
surgery ranged from 5.7 to 16.8 kg/m2. Excessive weight loss ranged between 25.4-
81.25% and 18.4-72.2%, after 1st and 2nd year of follow-up, respectively. Moreover, 2
years following surgery hypertension resolved in 9-98% of patients, hyperlipidemia
in 42-100%, arthralgia in 90% and sleep apnea in 68-100%. In the subset of diabetes
patients resolution of T2DM was observed in 33%-93% individuals 1 year post-
surgery. In the same timemean HbA1c was improved by 1.2-4.4 percentage points,
FBG was reduced by 37.8-107.2 mg/dl and BMI declined by 5.7-7.1 kg/m2. Bariatric
procedures led to complication rates ranging from 0 to 23.5% during the first post-
operative year and from 5 to 57% during the second year. Reported mortality was
low and did not exceed 0.47%. Additionally, surgery had beneficial effect on pa-
tients’ quality of life, which improved especially in physical, emotional and social
domains. CONCLUSIONS: Bariatric surgery is effective in achieving durable weight
loss and as well as improvement or resolution of T2DM and other co-morbidities.
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OBJECTIVES: Hypertension and obesity are associated with long-term complica-
tions of type 2 diabetes mellitus (T2DM). A systematic literature review assessed
the prevalence of these comorbidities in adults with T2DM in Asia. METHODS:
Electronic databases (PubMed, Embase, Cochrane Library) were searched for pub-
lications related to T2DM plus hypertension and/or obesity (English, 2001-2011).
Bibliographies of included studies were also examined. RESULTS:Of 2303 abstracts
identified, 38 observational studies presented relevant data across 14 countries/
regions in Asia. Prevalence rates reported here are for adults with T2DM. In China,
hypertension prevalence was 49.9%-60.6% when hypertension was defined by
blood pressure cutpoints of 140/90 mmHg and/or use of antihypertensive medi-
cine,whereas the prevalencewas 74.7%-76.5%whenblood pressure cutpointswere
reduced to 130/85. A study in Israel using cutpoints of 140/90, 130/85, and
130/80 mmHg found hypertension prevalence rates of 60.2%, 76.5%, and 85.8%,
respectively. In studies reporting prevalence by a single hypertension definition,
the prevalence rates ranged from 61.0% to 78.1% when the cutpoints were130/80
or 130/85 mmHg and 13.6% to 78.4% when the cutpoints were 140/90 mmHg.
Obesity prevalence data were limited. Cutpoints for defining obesity by body mass
index (BMI) or waist circumference (WC) varied among the studies. The obesity
prevalence rates by BMI were: Israel, 20.1%; Japan, 33.9%; Qatar, 53.8%; Taiwan,
38%-52.7%; Jordan, 58.6%; Saudi Arabia, 83.4%; Iran, 85.5%; and byWCwere: Japan,
24.3%-27.0%; South Korea, 37.2%; Pakistan, 61.5%; India, 67%. Few studies reported
comorbidity of both hypertension and obesity, with varying definitions of each
comorbidity. The prevalence of hypertension with obesity was: Saudi Arabia,
10.7%; Japan, 18.0%-20.6%; Jordan, 76.6%; Israel, 69.7%-93.3%. CONCLUSIONS: In
Asians, hypertension and obesity, separately or together, are common comorbidi-
ties of T2DM. Accurate, consistent reporting of their prevalence will help quantify
efforts needed to manage these comorbidities and their long-term health and cost
consequences.
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OBJECTIVES:The association of A1C’s variabilitywith developing newdiabetes has
been little studied. We aimed to evaluate the effect of visit-to-visit A1C variability
on the risk of developing new diabetes in healthy adults in Japan. METHODS:
Population-based, cohort study from 2005 to 2008 in Tokyo, Japan of healthy adults
not taking diabetes medication and with a HbA1c lower than 6.5% at baseline.
Based on annual measurement of serum HbA1c we calculated the annual visit-to-
visit variability, and used this as a predictor of new onset diabetes in amultivariate
logistic regression. RESULTS: At baseline, 14,587 people (50% female) with a mean
age of 51 years old (SD: 12 years, range: 23 to 92), a mean fasting plasma glucose
(FPG) level of 98.4 mg/dl (SD: 9.3 mg/dl) and a mean HbA1c level of 5.3 % (SD: 0.4 %)
had annual check-ups over 4 years. After adjusting for the other potential risk
factors new diabetes was predicted by the A1C variability (odds ratio (OR): 10.3 for
highest ( 0.16%)) versus the lowest quantile (0.08 %), 95%CI: 5.9 – 18.0) and by
the baseline A1C (OR: 55.2 for A1C of 6.0 – 6.4 % versus A1C of 5.0 %, 95% CI: 13.2
– 230). FPG (OR: 1.1, 95%CI: 1.1 – 1.2) and Smoker (OR: 1.8, 95%CO: 1.3 – 2.6) weakly
but also significantly related to develop the new diabetes. For predicting the devel-
opment of diabetes, the combination of the level of AIC at baseline and the vari-
ability (AUC for the ROC0.94) was superior to the level of A1C at baseline alone
(AUC0.89). CONCLUSIONS: Visit-to-visit variability in A1C independently added
to the baselineA1C in predicting the risk of developing newdiabetes for the healthy
adults. We should consider not only the baseline A1c level but also variability in
A1C to prevent development of the diabetes.
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OBJECTIVES:The FDAwarned on June 15, 2011 of the bladder cancer risk associated
with pioglitazone use. Therefore, we conducted a retrospective review of pioglita-
zone use in our hospital, to find out high risk patient, provide FDA safety advice by
using electronic message in computerized physician order entry system (CPOE),
aim to ensure physician aware of the risk at the moment of patient clinic visit.
METHODS: We included outpatients with pioglitazone use from January 1, 2006
through July 31, 2011. For high risk patients, who are male, prescribed pioglitazone
more than 1 year and cumulative dose reached 28000mg, clinical pharmacists will
established warning message in CPOE. The message was to inform physician the
patient was at high risk for bladder cancer, and should care about the symptoms of
bladder cancer, such as hematuria; urgent need to urinate or pain while urinating;
pain in back or lower abdomen. RESULTS: Overall 3196 patients had ever pre-
scribed pioglitazone. The mean age was 63.2  11.9 years, and 1519 (49%) of the
patients were male. Five (0.16%) patients with the diagnosis of bladder cancer.
There were 1874 patients with currently pioglitazone use, 629 (33.5%) patients pre-
scribed pioglitazonemore than 1 year, 160 (8.5%) patients cumulative dose reached
28000mg, and 75 (4%) of our patients were at high risk for bladder cancer. Eighteen
(24%) high risk patients were discontinued pioglitazone after FDA announcement,
another 18 (24%) patients because ofwarningmessage established by clinical phar-
macists. Twenty six (66.7%) patients have urine test, 5 (12.8%) with positive occult
blood. CONCLUSIONS: From the retrospective results, there was no association
between pioglitazone use and bladder cancer in our hospital. The communication
by using electronicmessage in CPOE enhanced the awareness of physician. Clinical
pharmacistswill prospectively establish thewarningmessage for patientwith high
risk.
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OBJECTIVES: To compare diabetes-related complications, utilizations and costs
between diabetes patients treated with DPP4i-based combinations (DPP4iMET or
DPP4iPIO) vs. SU-based combinations (SUMET or SUPIO).METHODS: Market-
Scan, a U.S. database of insured members, was analyzed to retrospectively com-
pare outcomes between patients treated with DPP4i and SU combinations. The
study sample consisted of T2DM patients who received DPP4i or SU combinations
and had continuous eligibility from 6months prior to and 12months following the
index date (date of combination therapy initiation). Rates of diabetic complica-
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tions, health care utilization, and costs in 12-month follow-up period were as-
sessed. Complications included microvascular (e.g. diabetic retinopathy), macro-
vascular (e.g. atherosclerosis), and other diabetic complications. Cox proportional
hazards models were used to compare complication rates, adjusting for baseline
characteristics. Generalized linearmodels/two-partmodelswere similarly used for
utilizations and costs. RESULTS: The study included 15,139 patients (47.0% female;
mean age 52.6 [SD8.1]) receiving DPP4i combinations and 41,602 patients (42.4%
female; mean age 51.9 [SD8.3]) receiving SU combinations. At baseline, DPP4i
patients had higher rates ofmedication use than SU patients (MET: 61.7% vs. 40.4%;
TZD: 23.0% vs. 11.8%; lipid-lowering: 53.2% vs. 35.4%; number of different medica-
tions: 7.2 [SD5.1] vs. 5.3 [SD4.9], respectively; all P0.0001). After adjustment,
hazard ratios of complications were significantly lower for patients treated with
DPP4i combinations (microvascular complications: 0.872, P0.0001;macrovascular
complications: 0.933, P0.0015; other complications: 0.921, P0.0001). DPP4i pa-
tients also had lower adjusted diabetes-related utilization incidence rate ratios
(hospitalization: 0.76; ER visits: 0.69; outpatient visits: 0.87; all P0.0001). DPP4i
patients incurred higher mean diabetes-related prescription drug costs ($1,629 vs.
$476, P0.0001) but lower all-cause medical services costs ($6731 vs. $7251,
P0.0001). CONCLUSIONS: Compared to SU combinations, DPP4i combinations are
associated with lower rates of diabetic complications and health care utilization.
While patients onDPP4i combination incur higher diabetes-related drug costs, they
were found to have lower all-cause medical-services costs.
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OBJECTIVES: The prevalence of diabetes in China is rising, and was recently esti-
mated as 9.7% in The China National Diabetes andMetabolic Disorders Study, with
a large proportion of patients previously undiagnosed. The costs of treating com-
plications in all patients and managing the disease in diagnosed patients are high.
The aim of this study was to estimate the annual cost of illness for all patients and
lifetime diabetes costs for diagnosed patients in China. METHODS: A model was
developed to estimate the cost of diabetes for 2011. Diabetes complication costs
were derived from hospital surveys in Beijing and Chengdu. Diabetes treatment
strategies were based on the intensive arm of the UK Prospective Diabetes Study
(UKPDS). The annual incidence and prevalence rates for major diabetic complica-
tions, including cardiovascular, renal, ocular, foot ulcer, neuropathy and treat-
ment-related events, were derived from international studies of diagnosed pa-
tients with baseline disease duration of less than ten years, including the UKPDS.
All patients were at risk of incurring complication costs, and only diagnosed pa-
tients could incur treatment and management costs. For diagnosed patients life-
time cost projections were made, discounted by 3% annually, using a validated
diabetes model. RESULTS: The 2011 cost of diabetes was estimated as CNY 13,326
per diagnosed and CNY 4,727 per undiagnosed patient, with the difference attrib-
utable to diabetes treatment and management costs. Based on a total population
approaching 1.4 billion and previously reported disease prevalence rates, the na-
tional cost of diabetes in 2011 was estimated as CNY 1,214 billion. In diagnosed
patients, a lifetime cost of CNY 301,716 per patient was estimated (or CNY 18,253
billion nationally); diabetes complications comprised 53% of total costs.
CONCLUSIONS: The costs of diabetes in China are high. Based on a Gross Domestic
Product (GDP) of CNY 47,156.4 billion for 2011, appropriate care for every diabetic in
China would cost 2.6% of GDP.
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OBJECTIVES: Data from the 2006 Malaysian National Health Morbidity Survey
showed that the overall prevalence of diabetes in Malaysia is over 11%. The high
prevalence of diabetes and themanagement of diabetes-related complications has
considerable implications in terms of health care spending, with 16% of overall
health care spending inMalaysia attributed to themanagement of diabetes in 2010.
The objective of the study was to estimate current direct costs associated with
diabetes-related complications in Malaysia.METHODS:Most direct costs of diabe-
tes complications were derived from interviews with three key opinion leaders in
the field of diabetes in Malaysia. Dialysis costs were sourced from published liter-
ature.Mean costswere then estimated calculated for first and subsequent years for
each event/complication. All costs are presented in 2011 Malaysian Ringgits (MYR)
(converted to US dollars [USD], exchange rate USD 1 to MYR 3.14). RESULTS: End-
stage renal disease was associated with the highest annual per patient costs, with
mean first year costs for hemodialysis and peritoneal dialysis being MYR23,500
(USD7,070) and MYR36,000 (USD11,465) per year, respectively. Costs of renal trans-
plant were MYR26,000 (USD8,280) in the year of transplant andMYR3,000 (USD955)
per year in subsequent years. Other complications associatedwith high direct costs
were amputation and prosthesis (MYR425 andMYR3,750, respectively [USD135 and
USD1,194, respectively]), cataract operation (MYR3,221, USD1,026) and myocardial
infarction (MYR1,233 [USD393] in year of event and MYR367 [USD117] per year in
subsequent years). Additionally, neuropathy was associated with mean costs of
MYR900 (USD287) in the first year and MYR675 (USD215) per year thereafter.
CONCLUSIONS: Diabetes is associated with a substantial economic burden in Ma-
laysia, and themanagement of diabetes related complications is likely to represent
a significant proportion of the overall costs. The cost data reported in this study
represents a useful resource for future economic evaluations of diabetes in Malay-
sia.
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OBJECTIVES: Indonesia has the fourth highest number of cases of diabetesmellitus
in the world. Estimates from 2010 indicated that approximately 7,000,000 people in
Indonesia had diabetes. Although diabetes-related complications are associated
with a considerable economic burden, there is a paucity of data on the costs of
diabetes in Indonesia. The aim of the present studywas to estimate the direct costs
associatedwithmanaging diabetes-related complications from a health care payer
perspective in Indonesia. METHODS: Literature review of EMBASE, PubMed, the
Cochrane Library and grey literature provided few publications to inform cost es-
timates. Costs were evaluated based on interviews with local expert physicians
and were collected for the first year of treatment and each subsequent year per
event/complication. Costs were classified into six main groups: cardiovascular
complications, renal complications, acute events, eye-disease, neuropathy and di-
abetic foot complications, and concomitant medications. Costs were expressed in
2011 Indonesian Rupiah (IDR) with US dollar (USD) conversions (exchange rate
USD1 to IRD8,940). RESULTS:Myocardial infarction was the most costly cardiovas-
cular complication with a first year cost of IDR202.7 million (USD22,673), followed
by stroke, unstable angina and heart failure. Renal complications were also signif-
icant contributors of cost with transplantation estimated to cost approximately
IDR192.5 million (USD21,532) in the first year and IDR45 million (USD5,033) in each
subsequent year. Hemodialysis cost over IDR89.3 million (USD9,994) annually and
peritoneal dialysis cost over IDR57.1million (USD6,391) each year. Themost expen-
sive ocular procedure was cataract surgery (IDR5.1 million [USD573]). Lower limb
amputation was themost costly of the diabetic foot complications (IDR21.2million
[USD2,375]). CONCLUSIONS: Estimates of complication costs suggest that the 7
million patients with diabetes represent a substantial economic burden in Indone-
sia. The data collected in this study represent a valuable resource to investigate the
economic impact of diabetes treatments in the Indonesian setting.
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OBJECTIVES: Diabetes is associated with a substantial and growing clinical and
economic burden in India, accounting for approximately 11% of national health
care expenditure in 2010. Moreover, the management of diabetes-related compli-
cations is the main contributor to the overall cost of the disease. The objective of
the study was to obtain current direct costs for the management of diabetes-re-
lated complications in India.METHODS: Direct costs of diabetes-related complica-
tions were derived from interviews with three expert diabetologists based in India,
with the exception of the costs of renal procedures, which were derived from
published, country-specific literature. Mean values based on all experts’ estimates
were calculated for first and subsequent years for each complication. Costs were
classified into 6 groups (management, cardiovascular complications, renal-compli-
cations, acute-events, eye-disease and neuropathy/foot ulcers). Costs are pre-
sented in 2011 Indian Rupees (INR) with equivalent US dollar (USD) values (ex-
change rate USD1 to INR50.23). RESULTS: At an individual patient level the most
expensive diabetes-related complication was end-stage renal disease, where both
peritoneal dialysis and hemodialysis were associated with direct annual costs of
INR788,059 and INR755,223, respectively, and renal transplant was associated with
costs of INR577,910 (USD11,505) in the year of transplant and INR295,522 (USD5,883)
in each subsequent year. The direct cost of cardiovascular complications was also
high; for examplemyocardial infarction cost approximately INR162,500 (USD3,235)
in the year of event and INR16,500 (USD328) in subsequent years. Gangrene
(INR55,000 [USD1,095] per event) and infect ulcer (INR27,500 [USD547] per event)
had the highest costs of the diabetic foot complications. CONCLUSIONS: In India,
direct costs associated with themanagement of diabetes-related complications, in
particular renal and cardiovascular complications, contribute significantly to the
economic burden associated with diabetes. Costs presented in this study will pro-
vide useful data for economic evaluations of diabetes interventions in India.
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OBJECTIVES: To estimate the direct medical cost for diabetes mellitus (DM) related
complications in China. METHODS: Data were obtained from a cross-sectional
survey of 20 internists of endocrine and metabolism departments in 20 hospitals
from September to November in 2011 in 9 cities of China. 11 internists worked in
tier 3 hospitals and 9 worked in tier 2 hospitals. All the internists who are depart-
ment director or deputy director were asked to give the average costs of complica-
tions treatment according to their clinical practice and retrospective medical re-
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